Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
Type:
Grant
Filed:
January 26, 2022
Date of Patent:
July 16, 2024
Assignee:
Poxel SA
Inventors:
Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sébastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
Type:
Grant
Filed:
August 13, 2021
Date of Patent:
March 5, 2024
Assignee:
Poxel SA
Inventors:
Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of genetic neurodegenerative diseases selected from adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN).
Type:
Grant
Filed:
March 26, 2021
Date of Patent:
December 26, 2023
Assignee:
POXEL
Inventors:
Sébastien Bolze, Pascale Fouqueray, Sophie Hallakou-Bozec
Abstract: The invention provides methods of synthesis of enantiopure deuterium enriched R-pioglitazone with structure of compound (IV), or a pharmaceutically acceptable salt thereof: The invention further provides chemical intermediates useful in the synthesis of compound (IV), and methods of synthesizing those intermediates.
Type:
Grant
Filed:
June 28, 2021
Date of Patent:
September 26, 2023
Assignee:
Poxel SA
Inventors:
Laure Françoise Valérie Navarre, Vincent Jacques, Sébastien Bolze
Abstract: The present invention provides a method for treating or preventing heart failure with preserved ejection fraction (HFPEF), wherein the method comprises administering to a patient having or at risk of developing HFPEF a therapeutically effective amount of imeglimin.
Abstract: Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.
Type:
Grant
Filed:
May 7, 2021
Date of Patent:
May 3, 2022
Assignee:
Poxel SA
Inventors:
Laure Françoise Valérie Navarre, Emeline Gardette, Sébastien Bolze, Sheila DeWitt, Vincent Jacques
Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
Type:
Grant
Filed:
March 9, 2020
Date of Patent:
March 8, 2022
Assignee:
POXEL SA
Inventors:
Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sebastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
Type:
Grant
Filed:
December 6, 2018
Date of Patent:
October 12, 2021
Assignee:
Poxel SA
Inventors:
Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
Type:
Grant
Filed:
March 5, 2019
Date of Patent:
September 21, 2021
Assignee:
Poxel SA
Inventors:
Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
Abstract: This invention pertains to a film-coated tablet comprising an inner core and an external coating, wherein the inner core comprises a high proportion of a specific triazine derivative, namely 2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine and pharmaceutically acceptable salts thereof, and a specific binder. It is also directed to the use of these tablets in the treatment of diabetes and/or complications thereof. This invention is further directed to a specific process for the manufacture of these film-coated tablets, which involves a granulation step in a high-shear mixer.
Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
Type:
Grant
Filed:
November 7, 2017
Date of Patent:
April 23, 2019
Assignee:
Poxel SA
Inventors:
Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
Type:
Grant
Filed:
February 19, 2018
Date of Patent:
September 11, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
Inventors:
Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
Type:
Grant
Filed:
September 10, 2014
Date of Patent:
February 20, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
Inventors:
Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
Abstract: The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases.
Type:
Grant
Filed:
December 28, 2010
Date of Patent:
June 14, 2016
Assignee:
Poxel
Inventors:
Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
Abstract: Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies.
Type:
Grant
Filed:
June 28, 2013
Date of Patent:
March 15, 2016
Assignee:
POXEL
Inventors:
Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
Abstract: The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives.
Type:
Grant
Filed:
June 9, 2011
Date of Patent:
March 1, 2016
Assignee:
POXEL
Inventors:
Pascale Fouqueray, Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze
Abstract: The invention relates to compounds of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with the activity of AMP-activated protein kinase (AMPK). Another object of the invention concerns the use of said compounds for enhancing glucose homeostasis, improving podocytopathy and/or decreasing the production of reactive oxygen species (ROS). The invention also relates to a method for in-vitro diagnosing diabetic nephropathy and a method for screening compounds that reduce podocytopathy, in each case by applying synaptopodin as biomarker.
Type:
Grant
Filed:
December 11, 2009
Date of Patent:
May 19, 2015
Assignee:
POXEL
Inventors:
Daniel Cravo, Sophie Hallakou-Bozec, Didier Mesangeau, Samer Elbawab